The Anticancer Power of the Immune System – New Perspectives for Patients with Triple-Negative Breast Cancer

The Anticancer Power of the Immune System – New Perspectives for Patients with Triple-Negative Breast Cancer

Triple-Negative Breast Cancer (TNBC) represents a heterogeneous disease that includes different subtypes and accounts for approximately 20% of all breast cancers (BC). TNBC is oestrogen receptor-negative, progesterone receptor-negative, and human epidermal growth factor receptor 2-negative. In addit...

Full description

Bibliographic Details
Main Author: Katarzyna Rygiel
Format: Article
Language:English
Published: European Medical Journal 2019-11-01
Series:European Medical Journal Oncology
Subjects:
checkpoint inhibitors
immunotherapy
programmed death-ligand 1 (pd-l1)
programmed cell death protein 1 (pd-1)
targeted therapy
triple-negative breast cancer (tnbc)
Online Access:https://www.emjreviews.com/oncology/article/the-anticancer-power-of-the-immune-system-new-perspectives-for-patients-with-triple-negative-breast-cancer/

Internet

https://www.emjreviews.com/oncology/article/the-anticancer-power-of-the-immune-system-new-perspectives-for-patients-with-triple-negative-breast-cancer/

Similar Items